Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
Abstract format and assignment number: Poster 0540
Presenting author: J. Meade Aguilar (USA)
Date: Saturday, 16th November 2024
In this retrospective study, the authors evaluated the relation between NSAID use and incident hypertension in a longitudinal inception cohort of patients with axial spondyloarthritis (axSpA) using data from a longitudinal French DESIR cohort of early spondyloarthritis with 72-month follow-up. It found no significant association between high-dose NSAID use and the development of hypertension. The anti-inflammatory effects of NSAIDs on disease activity might counterbalance the risk of incident hypertension that is known to occur in the general population.
The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis
Abstract format and assignment number: Oral presentation 0819
Presenting author: D. Poddubnyy (Germany)
Date: Saturday, 16th November 2024
ASAS presented its definition of ‘difficult-to-manage axSpA’ (D2M axSpA) at the 2024 ACR Convergence. The definition encapsulates treatment failure, suboptimal disease control, and physician or patient acknowledgment of problematic signs/symptoms in patients diagnosed with axSpA by a rheumatologist. “Treatment-refractory” disease is a part of the D2M group, which can be concluded after excluding other reasons for non-response and requires a history of specific treatment failure and the presence of objective signs of inflammatory activity.
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Abstract format and assignment number: Oral presentation 1464
Presenting author: L. Gossec (France)
Date: Sunday, 17th November 2024
The authors presented the interim analysis of the first ≥600 participants (pts) enrolled out of 1300 planned pts in PsABIOnd. The aim was to assess treatment persistence and achievement of clinical psoriatic arthritis (PsA) outcomes at 6 months. PsA pts had similar persistence on treatment with guselkumab or IL17i, and comparable rates of effectiveness across various PsA domains at 6 months.
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Abstract format and assignment number: Oral presentation 1756
Presenting author: J. Heberg (Denmark)
Date: Sunday, 17th November 2024
The authors aimed to assess the time to achieve low disease activity (LDA) from the initiation of a TNFi or an IL-17Ai, as well as the duration of achieved LDA, in patients with axSpA and 0, 1 or 2 prior TNFi treatments. The time to achieve LDA increased with the number of prior TNFi in both TNFi and IL-17Ai treatments. While the duration of LDA was shorter for TNFi-experienced than biologic-naïve patients initiating IL-17Ai, prior TNFi did not affect durability in patients initiating TNFi.
Exploring Weight Trends in Psoriatic Arthritis: Unraveling Effects of Drugs
Abstract format and assignment number: Oral presentation 2639
Presenting author: P Mehta (Canada)
Date: Monday, 18th November 2024
The authors aimed to study the change in weight with the use of csDMARDs, biologic (b)DMARDs, Janus kinase inhibitors (JAKi) and apremilast, along with other factors affecting weight across a cohort of patients with PsA. Significant weight loss was observed after initiation of IL17i, IL23i and csDMARDs in PsA, as compared to weight before initiation of these drugs. However, amongst the drugs, the use of TNFi and IL12/23i was associated with weight gain, whereas apremilast was associated with weight loss when compared across the cohort.
Jean-Guillaume Letarouilly MD PhD
Jean-Guillaume is a consultant rheumatologist at Lille University Hospital (France). His research interests include axial spondyloarthritis and psoriatic arthritis, the crosstalk with inflammatory bowel diseases and psoriasis, and difficult-to-treat axial spondyloarthritis and psoriatic arthritis.
He is a member of Young-GRAPPA and of the EMEUNET Visibility and Global Affairs Subcommittee.